PAMU
IBRX icon

Pictet Asset Management (UK)’s ImmunityBio IBRX Stock Holding History

Pictet Asset Management (UK)’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$4.32M Buy
302,345
+254,150
+527% +$4.2M ﹤0.01% 886
2021
Q1 		$1.14M Buy
+48,195
New +$1.25M ﹤0.01% 1039

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management (UK)'s IBRX Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its ImmunityBio (IBRX) stake by 527% in Q2 2021, buying an estimated $4.2M and bringing the position to 302,345 shares worth $4.32M. The position accounts for ﹤0.01% of the portfolio, ranked #886.

Pictet Asset Management (UK) first reported a position in IBRX in Q1 2021 and has held it in 2 quarters since. 125 funds tracked by Wall St. Rank hold IBRX as of Q2 2021.

  • Pictet Asset Management (UK) held 302,345 shares of ImmunityBio worth $4.32M as of Q2 2021.
  • Pictet Asset Management (UK) bought 254,150 ImmunityBio shares in Q2 2021, an estimated $4.2M.
  • ImmunityBio made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #886 holding.
  • Pictet Asset Management (UK) first reported a position in ImmunityBio in Q1 2021 and has held it in 2 quarters since.
  • 125 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.